Clinical trial / 2023
In patients with uncontrolled type 2 diabetes, add-on spirulina platensis significantly reduced HbA1c, fasting glucose, and improved lipid profiles.
Sixty patients with uncontrolled type 2 diabetes mellitus were randomized to receive either Spirulina platensis (2 g/day) or placebo for three months alongside usual metformin therapy. Compared to baseline, S. platensis supplementation resulted in significant reductions in HbA1c (decrease of 1.43, p < 0.001) and FBS (decrease of 24.94 mg/dL, p < 0.001). Total cholesterol dropped by 41.36 mg/dL, LDL-C dropped by 38.4 mg/dL, and triglycerides were significantly lower than controls (p < 0.001), while HDL-C showed a marginal increase (increase of 3 mg/dL, p < 0.001). No adverse events were reported.
- Study type
- Randomized, double-blind, placebo-controlled add-on trial
- Who was studied
- 60 patients with uncontrolled type 2 diabetes mellitus taking metformin
- What was measured
- HbA1c levels, fasting blood sugar, and lipid profiles (TC, LDL-C, TG, HDL-C)
THE PAPER
A randomized, double-blind placebo-controlled add-on trial to assess the efficacy, safety, and anti-atherogenic effect of spirulina platensis in patients with inadequately controlled type 2 diabetes mellitus.
Karizi SR, Armanmehr F, Azadi HG, Zahroodi HS, Ghalibaf AM, Bazzaz BSF, Abbaspour M, Boskabadi J, Eslami S, Taherzadeh Z. Phytother Res, 2023.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.